Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MMP 2200

Known as: MMP-2200, MMP2200 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
ABSTRACT Dopamine (DA)‐replacement therapy utilizing l‐DOPA is the gold standard symptomatic treatment for Parkinson's disease… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 6
2015
2015
Previous work in our laboratories provides preclinical evidence that mixed-action delta/mu receptor glycopeptides have equivalent… Expand
  • table 1
  • figure 2
  • figure 3
  • figure 1
  • figure 4
2014
2014
VIII. DISCLOSURE The authors of this presentation have nothing to disclose. V. SUMMARY • HLPC-EC and semi-quantitative western… Expand
  • figure 6
2012
2012
Endogenous opioid peptides enkephalin and dynorphin are major co-transmitters of striatofugal pathways of the basal ganglia. They… Expand
2011
2011
We have previously reported the chemistry and antinociceptive properties of a series of glycosylated enkephalin analogs… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2011
2011
In Parkinson's disease (PD), the consequence of dopaminergic denervation is an imbalance in the activity of the direct and… Expand
2008
2008
H2N-Tyr-d-Thr-Gly-Phe-Leu-Ser-(O-β-d-lactose)-CONH2 (MMP2200) is a novel glycopeptide opioid agonist with similar affinities for… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 5